We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis.
- Authors
Norborg, Hilde; Riise, Trond; Myhr, Kjell-Morten; Grytten, Nina; Wergeland, Stig
- Abstract
Background: For patients with MS, medication switches increase the risk of disease reactivation. Objective: Compare discontinuation rates due to treatment failure or side effects between teriflunomide and dimethyl fumarate, and investigate clinical variables affecting discontinuation rates. Methods: All patients who received teriflunomide or dimethyl fumarate at Haukeland University Hospital from 2013 until 2018 were identified. Clinical and demographic variables were extracted from the Norwegian MS Registry. Cause-specific Cox regression models estimated the rate of discontinuation due to treatment failure or side effects. Results: We included 354 patients treated with either dimethyl fumarate (n = 185) or teriflunomide (n = 169). We found 38% lower risk of discontinuation because of treatment failure for patients using dimethyl fumarate compared to teriflunomide (p < 0.05). In a treatment-naive subgroup (n = 183), we found a 38% reduced risk of discontinuation for any reason among patients using dimethyl fumarate (p < 0.05). There was no significant difference between treatment groups in discontinuation rate due to side effects, although more patients reported side effects when treated with dimethyl fumarate. Conclusion: Our findings suggests that dimethyl fumarate has a lower risk of discontinuation because of treatment failure among both treatment-experienced and treatment-naive patients.
- Subjects
DIMETHYL fumarate; TREATMENT failure; MULTIPLE sclerosis; TERMINATION of treatment; UNIVERSITY hospitals
- Publication
Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, Vol 7, Issue 2, p1
- ISSN
2055-2173
- Publication type
Article
- DOI
10.1177/20552173211022027